

1 **Phase 1 safety and pharmacokinetics studies of BRII-196 and BRII-198, SARS-**
2 **CoV-2 spike-targeting monoclonal antibodies**

3
4 Yao Zhang^{1,3,¶}, Xiaohua Hao^{2,¶}, Ji Ma³, Mingming Wang³, Yanyan Li³, Yang Liu³, Dong
5 Zhao², Wen Zhang², Chunming Li³, Li Yan³, Qing Zhu^{1,3,*}, Fujie Zhang^{2,*}

6
7 ¹ TSB Therapeutics, Beijing, China

8 ² Beijing Ditan Hospital, Capital Medical University, Beijing, China

9 ³ Bii Biosciences Inc., Durham, NC, US

10
11 *: Corresponding authors:

12 Qing Zhu

13 Email address: qing.zhu@briibio.com (QZ)

14 Fujie Zhang

15 Email address: treatment@chinaaids.cn (FZ)

16
17 ¶ These authors contributed equally to this work.

18 **Running title:** Safety and PK of COVID-19 mAbs in human

19 Abstract: 189/200 words

20 Text: 2546/3500 words

21 **Potential conflicts of interest:** authors were employees of TSB therapeutics, Bii

22 Biosciences, or Ditan Hospital when the study was conducted

23 **Financial support:** This study was sponsored by TSB Therapeutics, a subsidiary

24 company of Bii Biosciences

25

26

27 **Abstract**

28 **Background.** BR11-196 and BR11-198 are two anti-SARS-CoV-2 monoclonal
29 neutralizing antibodies with modified Fc region that extends half-life and are being
30 developed as cocktail therapy for the treatment of COVID-19. Safety, tolerability,
31 pharmacokinetics, and immunogenicity of BR11-196 and BR11-198 were investigated
32 in healthy adults.

33 **Methods.** Single ascending doses of BR11-196 and BR11-198 were evaluated in
34 parallel in the first-in-human, placebo-controlled phase 1 studies. A total of 32 healthy
35 adults were randomized and received a single intravenous infusion of 750, 1500, and
36 3000 mg of BR11-196 (n=12), BR11-198 (n=12), or placebo (n=8) and were followed
37 for 180 days.

38 **Results.** All infusions were well tolerated at infusion rates between 0.5 mL/min to 4
39 mL/min with no dose-limiting adverse events, deaths, serious adverse events, or any
40 systemic or local infusion reactions. Most treatment-emergent adverse events were
41 isolated asymptomatic laboratory abnormalities of Grade 1-2 in severity. Each mAb
42 displayed pharmacokinetics expected of Fc-engineered human IgG1 with mean
43 terminal half-lives of approximately 46 days and 76 days, respectively, with no
44 evidence of significant anti-drug antibody development.

45 **Conclusions.** BR11-196 and BR11-198 were well-tolerated. Clinical results support
46 further development as therapeutic or prophylactic options for SARS-CoV-2
47 infection.

48 **Keywords.** SARS-CoV-2; monoclonal antibody therapy; BR11-196; BR11-198

49 **Clinical Trials Registration.** NCT04479631 and NCT04479644

50 **Funding:** These studies were sponsored by TSB Therapeutics.

51 **Background**

52 As of March 2021, globally, over 120 million people have been infected by SARS-
53 CoV-2, resulting in more than 2.6 million death by Coronavirus Disease 2019
54 (COVID-19). The number of cases continues to rise[1].

55 The development of safe and effective therapeutics represents a key strategy to curb
56 COVID-19 mortality and morbidity. Several approved medications (e.g., chloroquine,
57 hydroxychloroquine, lopinavir/ritonavir) have been "repurposed" and evaluated, none
58 of which have been shown associated with improved clinical outcomes[2, 3]. There
59 have been limited treatment options, including remdesivir, dexamethasone, and
60 convalescent plasma, that demonstrated clinical efficacy in subsets of patients with
61 COVID-19[4-7].

62 Neutralizing monoclonal antibodies (mAbs) represent a promising therapeutic option
63 in preventing and treating known and emerging infectious diseases, including
64 viruses[8]. Recent clinical trials of mAbs reported positive results indicating
65 virological and clinical benefits among outpatients with COVID-19 [9, 10]. In
66 addition, several COVID-19 vaccines offering >90% protection have become available

67 for emergency use [11, 12]. However, recent data showed that several mutations
68 identified in the receptor binding domain (RBD) of spike protein in the emerging new
69 variants conferred reduced activity to neutralization by the antibodies that were
70 developed as a therapy for treatment or elicited by vaccines for prevention [13, 14].
71 These emergent variants present new challenges for mAb therapy and threaten the
72 protective efficacy of current vaccines and mAbs. Therefore, additional mAb
73 treatment options, especially a cocktail of antibodies targeting distinct epitopes, are
74 needed as a critical strategy to reduce the generation and selection of resistant viruses
75 during treatment and ensures binding and neutralization of the antibodies to new
76 variants.

77 BR11-196 and BR11-198, two recombinant human IgG1 mAbs that target the distinct
78 epitope regions in RBD in coronavirus spike glycoproteins non-competitively, are
79 under clinical development as a cocktail for the treatment of COVID-19 in
80 outpatients. BR11-196 and BR11-198 are derived directly from human B cells of
81 patients who recovered from COVID-19 [15] with effective neutralizing activity
82 against not only the original isolate of SARS-CoV-2 but also the new variants of
83 concerns, including B.1.351 (as known South African variant) and P1 from Brazil [16,
84 17]. BR11-196 and BR11-198 are engineered with a triple-amino-acid
85 (M252Y/S254T/T256E [YTE]) substitution in the fragment crystallizable (Fc) region
86 to allow an extended half-life [18, 19] and reduced Fc γ receptor binding for potential
87 risk of Fc-mediated antibody dependent enhancement (ADE) (unpublished data).

88 The back-to-back first-in-human phase 1 studies in healthy adult participants were
89 designed and conducted to evaluate the safety, tolerability, and pharmacokinetics (PK)
90 of BR11-196 and BR11-198 individually before initiating clinical studies of BR11-196
91 and BR11-198 in combination in patients.

92 **Methods**

93 **Study design and participants**

94 BRII-196-001 and BRII-198-001 are two first-in-human phase 1, randomized, single-
95 blind, placebo-controlled, single ascending dose escalation studies in which BRII-196
96 and BRII-198 were evaluated respectively among healthy adults. These studies were
97 conducted at a single phase 1 unit in China from July 2020 to February 2021
98 (registered at ClinicalTrials.gov under registration number NCT04479631 and
99 NCT04479644). The study protocol, amendments, and informed-consent forms were
100 reviewed and approved by Ethical Review Committee at the site. This study was
101 conducted in accordance with the International Conference on Harmonisation
102 Guidance for Good Clinical Practice guidelines and all applicable local regulatory
103 requirements and laws. Participants provided written informed consent before any
104 study-related procedures were performed.

105 Inclusion and exclusion criteria for the two studies were identical. Eligible
106 participants were healthy male or female adults aged 18 to 49 years, had a body
107 weight ≤ 100 kg and a body mass index of 18-24 kg/m², and were in good health
108 determined by no clinically significant findings from medical history, physical
109 examination including vital signs, electrocardiogram (ECG), and clinical laboratory
110 assessments. Women were not pregnant or lactating. Exclusion criteria included a
111 history of SARS-CoV-2 infection or exposure, a history of severe allergic reactions,
112 use of any medications that were started within 14 days before randomization, a
113 positive test for human immunodeficiency virus (HIV) or hepatitis B virus or hepatitis
114 C virus, a history of drug or alcohol abuse within 1 year before the screening, or any
115 history of a medical or psychiatric condition that would place them at risk or interfere

116 with study participation. Participants were also excluded if they were unwilling to use
117 necessary contraception during the study. A complete list of exclusion criteria is
118 included in [Supplementary Material 1](#).

119 **Study Procedures**

120 Three dose-level cohorts (750, 1500, and 3000 mg) were included to evaluate each
121 mAb and were initiated in a dose-escalation design. In each cohort, participants were
122 randomized at a 3:1 ratio to receive either the single mAb (n=3 or 6) or placebo (n=1
123 or 2). mAbs or placebo was dispensed into normal saline and was administered via
124 intravenous infusion on Day 1. The infusion started at the initial rate of 0.5 mL/min,
125 gradually increasing to a maximum rate of 4 mL/min. The participants were masked
126 to the treatment assignment and were admitted to the phase 1 unit for monitoring for 7
127 days post-dosing. The first participant in each cohort who received mAb infusion was
128 monitored for 24 hours before administering study intervention to the subsequent
129 participants. A Safety Review Committee made Dose-escalation recommendations
130 upon review of predefined safety data.

131 Vital signs, physical examinations, safety laboratory tests including hematology and
132 chemistry, and ECG were obtained before and after study drug administration on days
133 2, 4, 6, 8, 15, 22, 31, 61, 91, 121, 151, and at the end of the study on day 181. All
134 adverse events (AEs), including infusion reactions and serious adverse events (SAEs)
135 occurring throughout the trial, were recorded and assessed by study physicians at the
136 site. AEs were coded with the Medical Dictionary for Regulatory Activities
137 (MedDRA) version 23.1, and severity was graded using the Common Terminology
138 Criteria for Adverse Events (CTCAE) version 5.0, November 27, 2017.

139 **Pharmacokinetics and Immunogenicity Assessments**

140 The pharmacokinetics parameters were evaluated using blood samples collected
141 before dosing, at 3 and 8 hours post dose, and days 2, 4, 6, 8, 15, 22, 31, 61, 91, 121,
142 151, and 181. BR11-196 or BR11-198 serum concentrations were measured using
143 validated enzyme linked immunosorbent assays (ELISA) with the lower limit of
144 quantitation (LLOQ) at 150 ng/mL. Serum samples for anti-drug antibody (ADA)
145 assays were collected at the following time points: pre-dose on day 1 and at days 15,
146 31, and 181. Two validated titer-based 3-stage ELISA assays were used to detect
147 presences of ADAs from subjects over the study durations.

148 **Study Outcomes**

149 Primary endpoints were incidence of adverse events (AEs) and change from pre-dose
150 baseline in clinical assessments, including vital signs, ECG readings, and laboratory
151 results. Secondary endpoints included the pharmacokinetics profiles and presence of
152 ADAs to BR11-196/BR11-198 in samples collected after dosing for up to 180 days.

153 **Statistical Analysis**

154 The sample size of each study was consistent with a phase 1 first-in-human study. The
155 safety analysis included all participants who were randomized and received any dose
156 of the study drug. Categorical and continuous data were summarized descriptively.

157 Participants were analyzed according to the study drug they received. Participants
158 receiving placebo in different cohorts of each study were pooled in the analysis.

159 The PK parameters were estimated by non-compartmental analyses using WinNonlin
160 module in the Phoenix Platform (version 8.3.1.5014, Certara Inc., Princeton, NJ
161 08540). Calculations were performed prior to rounding, and nominal sampling times
162 were used in the pharmacokinetic analysis. All pharmacokinetic parameters and

163 summary statistics are reported to 3 significant digits except for T_{\max} (reported in
164 median values), which is reported to 1 decimal place.

165 **Results**

166 From July 12, 2020, to August 10, 2020, a total of 135 participants were screened,
167 with 16 and 17 eligible and enrolled for BR11-196-001 and BR11-198-001 studies,
168 respectively (**Figure 1**). The demographics of the study population are summarized in
169 **Table 1**, consisting of 28 (84.8%) men and 5 women with a median age of 33.0 years
170 and a median BMI of 21.9 kg/m².

171 A total of 12 participants received a single dose of BR11-196 IV infusion, 12
172 participants received a single dose of BR11-198 IV infusion, and 8 participants
173 received placebo (normal saline). One participant randomized in BR11-198-001 study
174 did not receive the infusion because of elevated blood pressure before dosing. All
175 participants received their full planned dose except for 3 participants assigned to 750
176 mg of BR11-196 and 1 participant assigned to placebo for whom the received volume
177 was approximately 10% less than the intended volume due to the remaining volume
178 left within the infusion set. All participants dosed have completed study visits. Total
179 infusion duration for BR11-196 or BR11-198 at investigated dose levels were 1.53-1.70
180 hours (750 mg), 2.27-2.43 hours (1500 mg), and 3.58-3.75 hours (3000 mg)
181 ([Supplementary Table 1](#)).

182 **Safety**

183 BR11-196 and BR11-198 administration was safe and well-tolerated. No deaths,
184 serious AEs, treatment-emergent adverse events (TEAEs) leading to early
185 termination, or infusion-related reactions occurred during the study. Adverse events

186 reported in BR11-196-001 and BR11-198-001 are summarized in **Table 2** and **Table 3**,
187 respectively. 26 (81%) participants had at least one treatment-emergent adverse
188 events, including 18 (75%) participants receiving BR11-196 or BR11-198 compared to
189 8 (100%) participants receiving placebo. Overall incidences of adverse events were
190 balanced between groups receiving BR11-196 or BR11-198 and placebo. The most
191 common TEAEs were isolated asymptomatic laboratory abnormalities of CTCAE
192 Grade 1 or 2 in severity that did not require medical intervention and typically
193 normalized or returned to baseline level within four weeks ([Supplementary Table 2](#)).
194 Seven out of 24 participants had 8 Grade 1 or 2 adverse events that were considered
195 by the investigators as related to BR11-196 or BR11-198, including increased blood
196 total bilirubin, increased alanine aminotransferase, decreased neutrophil count, and
197 decreased white blood cell count ([Supplementary Table 3](#)). No safety issues were seen
198 with respect to vital signs or ECG measurements. No dose-dependent pattern of any
199 adverse events was observed.

200 **Pharmacokinetics**

201 Pharmacokinetic data were available for a total of 12 participants each for BR11-196
202 and BR11-198 over the 181-day study duration. Following a single intravenous
203 infusion of BR11-196 or BR11-198 at 750, 1500, and 3000 mg, mean serum PK
204 parameters, including C_{max} and AUC, increased in an approximately dose-
205 proportional manner (**Table 4, Figure 2**). The mean systemic serum clearances were
206 75.4 and 57.0 mL/day for BR11-196 and BR11-198, respectively. The mean terminal
207 half-lives ($t_{1/2}$) of BR11-196 and BR11-198 were 44.6-48.6 days and 72.2-83.0 days.
208 The relatively shorter terminal half-life of BR11-196 correlated with slightly higher
209 systemic clearance.

210

211 **ADA Response**

212 In BR11-196-001 study, a total of 4 out of 12 participants had positive ADA samples in
213 the screening assay, but all tested negative in the follow-up confirmatory assay. In
214 BR11-198-001 study, one participant who received BR11-198 had positive ADA
215 samples in the screening assay but later confirmed negative in the tier-2 confirmatory
216 assay.

217 **Discussion**

218 BR11-196 and BR11-198 are fully human mAbs that bind to noncompeting epitope
219 regions on the RBD of SARS-CoV-2 S glycoprotein that interacts with the
220 angiotensin-converting enzyme 2 (ACE2) to enter human cells [20]. Therefore, they
221 neutralize virus infection by preventing virus binding to ACE2, blocking virus entry
222 and subsequent virus infection as demonstrated in vitro and in vivo [15, 21]. The

223 combined use of 2 independently neutralizing antibodies is likely to reduce the risk of
224 treatment failure from the development of virus escape mutants or new variants that
225 may arise during an outbreak. Currently approved COVID -19 vaccines were
226 constructed against the original virus, of which attenuation of serum neutralization
227 activity has been observed[14, 22]. In a recent trial conducted in South Africa, the
228 ChAdOx1 nCoV-19 vaccine did not protect against mild-to-moderate COVID-19 due
229 to the B.1.351 variant [23]. Pseudo viruses harboring mutations found in B.1.351
230 South Africa origin, P.1 Brazil origin, B.1.526 New York origin, L452R, and the spike
231 protein from the California origin variant lineage B.1.427/B.1.429, had significantly
232 reduced susceptibility to bamlanivimab [24], a mAb authorized for emergency use. In
233 addition, its approved cocktail with etesevimab under EUA was also tested inactive
234 against the live virus of B.1.351 South Africa [17]. As some of these variants are
235 beginning to spread around the world, it has posed a real threat to vaccine and
236 antibody therapies. By contrast, BR11-196 and BR11-198 cocktail retained their
237 neutralizing activity against all variants tested, including B1.1.7 UK variant, B1.357
238 South Africa variant, and P1 Brazilian variants[16, 17], thereby could provide more
239 treatment options to patients.

240 In these first-in-human clinical studies, intravenous administration of BR11-196 and
241 BR11-198 were both safe and well-tolerated in healthy adult participants receiving a
242 single dose up to 3000 mg, with no infusion reactions or AEs leading to adjustment or
243 discontinuation of the infusion. Study participants were followed up to 180 days post-
244 dosing considering the expected prolonged half-lives of the mAbs. Except for one
245 SAE, one Grade 4 elevation of creatine phosphokinase, and one Grade 3 elevation of
246 triglycerides, all deemed as not related to study drugs, all AEs reported were Grade 1-
247 2 in severity, with the majority being isolated asymptomatic transient laboratory

248 abnormalities. There were no safety concerns regarding vital signs or ECGs. The
249 safety observations in these phase 1 studies are consistent with the expected safety
250 profile of human IgG1 mAbs in healthy subjects with no endogenous target.

251 With YTE modification, both BR11-196 and BR11-198 demonstrated anticipated 2-3
252 folds half-life extension in healthy adult subjects. In comparison with BR11-198, the
253 relatively shorter half-life observed with BR11-196 correlates with slightly higher
254 systemic clearance. As both antibodies showed comparable increased binding
255 affinities to human and cynomolgus monkey FcRns at pH 6.0 in vitro (unpublished
256 data), different molecular properties such as charge variants, glycan profiles, and
257 overall thermal stability might contribute to the observed differences. With up to a 3-
258 week optimal treatment window for neutralizing antibodies for COVID-19 patients,
259 both antibodies are expected to provide comparable target coverage at the same dose
260 level.

261 BR11-196 and BR11-198 have several advantages that may facilitate their use for the
262 treatment and prevention of SARS-COV-2 infections. First, mAbs targeting specific
263 viral epitopes, including BR11-196 and BR11-198, belong to a platform technology
264 associated with a favorable safety profile. Findings regarding safety and tolerability in
265 phase 1 trials of BR11-196 and BR11-198 are consistent with the expectation, which
266 support an expedited development towards approval for future clinical use. Second,
267 targeting distinct viral epitopes in the RBD of SARS-COV-2 spike protein non-
268 competitively, BR11-196 and BR11-198 can be used in combination to provide additive
269 antiviral effect, reduce the generation of resistant viruses to treatment, and retain
270 activity against emergent naturally occurring variants as mentioned above. Third,
271 BR11-196 and BR11-198 are engineered with YTE substitution in the Fc region to
272 allow an extended half-life, demonstrated in the pharmacokinetic findings from both

273 phase 1 studies, with which BR11-196 and BR11-198 can potentially maintain an
274 adequate drug coverage over an extended period of time and subsequently are better
275 positioned for prophylactic use. Lastly, while YTE improves the half-life of the
276 antibody, it also reduced binding activity of BR11-196 and BR11-198 against human
277 Fc γ receptors, thereby minimizing the potential risk of Fc-mediated antibody
278 dependent enhancement of diseases.

279 In summary, BR11-196 and BR11-198 were generally safe and well-tolerated in healthy
280 adult participants. Pharmacokinetic and immunogenicity assessments demonstrated
281 linear pharmacokinetics with prolonged half-lives and no ADA development up to
282 180 days after a single dose. These findings support further development of BR11-196
283 and BR11-198 for the treatment and prophylaxis of SARS-COV-2 infection in the
284 pandemic outbreak. BR11-196 and BR11-198 combination is currently under
285 development in ACTIV-2, a platform phase 2/3 clinical study, for treatment of
286 COVID-19 in outpatients [25].

287

288 **Supplementary Materials and Data**

289 Supplementary materials and data are available at *The Journal of Infectious Diseases*
290 online. Consisting of materials and data provided by the authors to benefit the reader,
291 the posted materials are not copyedited and are the sole responsibility of the authors,
292 so questions or comments should be addressed to the corresponding author.

293 **Acknowledgment.**

294 The authors thank all the study participants in these clinical studies, without whom the
295 studies would not have been possible. We thank Dr Yibo Zhou, Jianmin Jing, and

296 Yonghong Mang, for their contributions in the studies. We also thank D.Margolis for
297 critically reviewing the manuscript and Dr. Chan Gao for her assistance with
298 formatting/editing and submission.

299 **Financial support.** These trials were sponsored by TSB Therapeutics, a subsidiary company of
300 Brii Biosciences. Y.Z., J.M., Y.L., Y.Y.L., M.W., C.L., L.Y., and Q.Z. are employees of Brii
301 Biosciences. Y.Z. and Q.Z. are employees of TSB Therapeutics. F.J.Z. received support from TSB
302 for participation as a principal investigator in the study.

303 **Author contributions:** Brii Biosciences was involved in and the study design, collection, analysis
304 and interpretation of data, the writing of this report, and the decision to submit this manuscript for
305 publication. F.J.Z., X.H.H, D.Z., and W.Z. reviewed protocol, and were responsible for study
306 implementation and data collection at the study site. All authors at Brii Biosciences had access to
307 all study data for review, participated in interpretation of the data and in drafting and revising the
308 article for important intellectual content, and provided final approval of the submitted manuscript.
309 All authors assume responsibility for the integrity and completeness of the reported data. Y.Z.,
310 J.M., Y.L., and Q.Z prepared the manuscript.

311 **Potential conflicts of interest.** Y.Z., J.M., Y.L., Y.L., M.W., C.L., L.Y., and Q.Z. are employees of
312 Brii Biosciences. Y.Z. and Q.Z. are employees of TSB Therapeutics. All other authors report no
313 potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential
314 Conflicts of Interest.

315 **References**

- 316 1. Johns_Hopkins_Coronavirus_Resource_Center. COVID-19 Map. Available at:
317 <https://coronavirus.jhu.edu/map.html>. Accessed Mar 17 2021.
- 318 2. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe
319 Covid-19. N Engl J Med **2020**; 382:1787-99.
- 320 3. SolidarityTrialConsortium WHO, Pan H, Peto R, et al. Repurposed Antiviral Drugs for Covid-19

- 321 - Interim WHO Solidarity Trial Results. *N Engl J Med* **2021**; 384:497-511.
- 322 4. Libster R, Pérez Marc G, Wappner D, et al. Early High-Titer Plasma Therapy to Prevent Severe
323 Covid-19 in Older Adults. *N Engl J Med* **2021**; 384:610-8.
- 324 5. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report.
325 *N Engl J Med* **2020**; 383:1813-26.
- 326 6. Group RC, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19. *N*
327 *Engl J Med* **2021**; 384:693-704.
- 328 7. Simonovich VA, Burgos Pratz LD, Scibona P, et al. A Randomized Trial of Convalescent Plasma
329 in Covid-19 Severe Pneumonia. *N Engl J Med* **2021**; 384:619-29.
- 330 8. Jin Y, Lei C, Hu D, Dimitrov DS, Ying T. Human monoclonal antibodies as candidate therapeutics
331 against emerging viruses. *Front Med* **2017**; 11:462-70.
- 332 9. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients
333 with Covid-19. *N Engl J Med* **2021**; 384:229-37.
- 334 10. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody
335 Cocktail, in Outpatients with Covid-19. *N Engl J Med* **2021**; 384:238-51.
- 336 11. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19
337 Vaccine. *N Engl J Med* **2020**; 383:2603-15.
- 338 12. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2
339 Vaccine. *N Engl J Med* **2021**; 384:403-16.
- 340 13. Liu H, Wei P, Zhang Q, et al. 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to
341 Bamlanivimab in vitro. *bioRxiv* [Preprint] February 16, 2021 [cited 2021 Apr 8]. Available from:
342 <https://doi.org/10.1101/2021.02.16.431305>

- 343 14. Wu K, Werner AP, Koch M, et al. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.
344 N Engl J Med 2021.
- 345 15. Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection.
346 Nature 2020; 584:115-9.
- 347 16. Wang R, Zhang Q, Ge J, et al. SARS-CoV-2 variants resist antibody neutralization and broaden
348 host ACE2 usage. bioRxiv [Preprint] March 15, 2021 [cited 2021 Apr 8]. Available from:
349 <https://doi.org/10.1101/2021.03.09.434497>.
- 350 17. Wang P, Nair MS, Liu L, et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7.
351 bioRxiv [Preprint] January 26, 2021 [cited 2021 Apr 8]. Available from:
352 <https://doi.org/10.1101/2021.01.25.428137>.
- 353 18. Robbie GJ, Criste R, Dall'acqua WF, et al. A novel investigational Fc-modified humanized
354 monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob
355 Agents Chemother 2013; 57:6147-53.
- 356 19. Saunders KO. Conceptual Approaches to Modulating Antibody Effector Functions and
357 Circulation Half-Life. Front Immunol 2019; 10:1296.
- 358 20. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Velesler D. Structure, Function, and
359 Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 2020; 181:281-92.e6.
- 360 21. Ge J, Wang R, Ju B, et al. Antibody neutralization of SARS-CoV-2 through ACE2 receptor
361 mimicry. Nature communications 2021; 12:250.
- 362 22. Liu Y, Liu J, Xia H, et al. Neutralizing Activity of BNT162b2-Elicited Serum. New England Journal
363 of Medicine 2021; 0:null.
- 364 23. Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine

365 against the B.1.351 Variant. New England Journal of Medicine 2021; 0:null.

366 24. Moruf A. Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) Of

367 Bamlanivimab. U.S. Food and Drug Administration, 2021:26.

368 25. Large clinical trial will test combination monoclonal antibody therapy for mild/moderate

369 COVID-19. Available at: [https://www.nih.gov/news-events/news-releases/large-clinical-trial-will-](https://www.nih.gov/news-events/news-releases/large-clinical-trial-will-test-combination-monoclonal-antibody-therapy-mild-moderate-covid-19)

370 [test-combination-monoclonal-antibody-therapy-mild-moderate-covid-19](https://www.nih.gov/news-events/news-releases/large-clinical-trial-will-test-combination-monoclonal-antibody-therapy-mild-moderate-covid-19). Accessed March 24

371 2021.

372

Figure 1 Trial Profiles




Figure 2. Observed Mean (\pm Standard Deviation) Serum Concentration - Time Profiles of BRII-196 and BRII-198 Following A Single Intravenous Infusion Administration to The Healthy Adult Subjects




Table 1 Participant Demographics and Baseline Characteristics

	BRII-196-001				BRII-198-001			
	750 mg (n=3)	1500 mg (n=6)	3000 mg (n=3)	Placebo (n=4)	750 mg (n=3)	1500 mg (n=7)	3000 mg (n=3)	Placebo (n=4)
Median age, years	22.0	32.5	34.0	33.5	30.0	33.0	30.0	37.5
Men	3 (100%)	4 (67%)	3 (100%)	3 (75%)	2 (67%)	7 (100%)	3 (100%)	3 (75%)
Women	0	2 (33%)	0	1 (25%)	1 (33%)	0	0	1 (25%)
Race								
Han, Chinese	3 (100%)	6 (100%)	2 (67%)	3 (75%)	3 (100%)	6 (86%)	3 (100%)	4 (100%)
Other, Chinese	0	0	1 (33%)	1 (25%)	0	1 (14%)	0	0
Median body-mass index, kg/m ²	22.80	21.15	21.60	22.90	23.70	21.00	22.30	23.10

Table 2 Summary of Adverse Events of BRII-196-001 Study

	BRII-196 750mg (n=3)	BRII-196 1500mg (n=6)	BRII-196 3000mg (n=3)	Placebo (n=4)
Participants with any TEAE	3 (100%)	5 (83%)	2 (67%)	4 (100%)
Participants with Grade 1 TEAE	3 (100%)	5 (83%)	2 (67%)	4 (100%)
Participants with Grade 2 TEAE	1 (33%)	3 (50%)	0	2 (50%)
Participants with Grade 3 or above TEAE	0	0	0	0
Participants with serious TEAE	0	0	0	0
Participants with infusion reaction TEAE	0	0	0	0
Participants with TEAEs related to study drug	1 (33%)	3 (50%)	0	0
Participants with any TEAE leading to discontinuation of study drug	0	0	0	0
Death	0	0	0	0
Number of participants with AEs by MedDRA SOC ^a				
Investigations	3 (100%)	4 (67%)	2 (67%)	4 (100%)
Infections and infestations	1 (33%)	0	0	2 (50%)

TEAE=treatment-emergent adverse event. SOC=system organ class.

Participants who experienced the same AE on more than one occasion (based on the specific category) are counted once in each relevant category. Percentages are based on the number of participants in the treatment group.

^a Only SOCs experienced by ≥ 2 participant or with the maximum severity category \geq Grade 2 are included.

Table 3 Summary of Adverse Events of BR11-198-001 Study

	BR11-198 750mg (n=3)	BR11-198 1500mg (n=6)	BR11-198 3000mg (n=3)	Placebo (n=4)
Participants with any TEAE	3 (100%)	5 (83%)	0	4 (100%)
Participants with Grade 1 TEAE	2 (67%)	5 (83%)	0	3 (75%)
Participants with Grade 2 TEAE	1 (33%)	0	0	1 (25%)
Participants with Grade 3 or above TEAE	0	2 ^a (33%)	0	1 ^b (25%)
Participants with serious TEAE	0	0	0	1 ^b (25%)
Participants with infusion reaction TEAE	0	0	0	0
Participants with TEAEs related to study drug	2 (67%)	1 (17%)	0	0
Participants with any TEAE leading to discontinuation of study drug	0	0	0	0
Death	0	0	0	0
Number of participants with AEs by SOC ^c				
Investigations	3 (100%)	4 (67%)	0	3 (75%)
Gastrointestinal disorders	1 (33%)	1 (17%)	0	0
Injury, poisoning and procedural complications	0	0	0	1 (25%)

TEAE=treatment-emergent adverse event. SOC=system organ class.

Participants who experienced the same AE on more than one occasion (based on the specific category) are counted once in each relevant category. Percentages are based on the number of participants in the treatment group.

^a 1 participant had an elevated blood creatine phosphokinase of Grade 4 after excessive exercise, and 1 participant had an increased blood triglycerides of Grade 3 on Day 181. Both events were not considered as related to the study drug by the investigators and normalized within 1-3 weeks.

^b 1 participant receiving placebo had a serious TEAE (bilateral traumatic foot fracture leading to hospitalization, which was also reported as a Grade 3 TEAE). The participant recovered after surgery.

^c Only SOCs experienced by ≥ 2 participant or with the maximum severity category \geq Grade 2 are included.

Table 4 BRII-196 and BRII-198 Pharmacokinetic Parameters Following A Single Intravenous Infusion Administration to The Healthy Adult Participants

Antibody	Dose (mg)	Number of Subject	C _{max} (µg/mL)	T _{max} (hour)	t _{1/2} (day)	CL (mL/day)	V _{ss} (L)	AUC _{last} (day*µg/mL)	AUC _{inf} (day*µg/mL)
BRII-196	750	3	268 (19.9)	4.6	48.6 (4.56)	84.7 (10.5)	5.34 (0.500)	8240 (764)	8940 (1040)
	1500	6	584 (75.1)	5.4	46.0 (8.09)	72.4 (8.40)	4.50 (0.208)	19300 (2430)	20900 (2380)
	3000	3	1300 (91.7)	6.6	44.6 (6.75)	72.2 (4.11)	4.35 (0.289)	38900 (2510)	41700 (2300)
BRII-198	750	3	244 (35.5)	4.7	75.9 (8.97)	59.4 (5.54)	6.17 (0.760)	10400 (911)	12700 (1240)
	1500	6	509 (107)	5.4	72.2 (8.45)	57.4 (9.50)	5.76 (0.981)	20900 (2950)	26800 (4700)
	3000	3	1017 (149)	6.8	83.0 (37.6)	53.9 (8.90)	6.07 (2.20)	42800 (9680)	56600 (8900)

SD=standard deviation, C_{max}=observed maximum serum concentration, T_{max}=time to reach observed maximum serum concentration, t_{1/2}=terminal half-life, CL=systemic clearance, V_{ss}=volume of distribution at steady state, AUC_{last}=area under the concentration–time curve from time zero to the last measurable concentration, AUC_{inf}=area under the concentration–time curve from time zero to infinity. All parameters are reported in three significant figures except T_{max} that is reported with median values.

Supplementary Tables

Supplementary Table 1. Infusion Related Parameters

Antibody	Dose	Number of Participants	Total Volume Infused (ml, median [min, max])	Total Infusion Duration (h, median [min, max])
BR11-196	750 mg	3	114 (110, 116)	1.57 (1.53, 1.57)
	1500 mg	6	250 (250, 250)	2.32 (2.27, 2.43)
	3000 mg	3	500 (500, 500)	3.60 (3.58, 3.70)
	Placebo	4	250 (125, 500)	2.30 (1.55, 3.65)
BR11-198	750 mg	3	125 (125, 125)	1.67 (1.65, 1.70)
	1500 mg	6	250 (250, 250)	2.33 (2.28, 2.43)
	3000 mg	3	500 (500, 500)	3.73 (3.70, 3.75)
	Placebo	4	250 (125, 500)	2.32 (1.67, 3.73)

Supplementary Table 2. Adverse Events by System Organ Class and Preferred Term

Antibody	System Organ Class	750 mg (n=3)	1500 mg (n=6)	3000 mg (n=3)	Placebo (n=4)
	Preferred Term				
BR11-196	Investigations	3 (100%)	4 (67%)	2 (67%)	4 (100%)
	White blood cell count decreased	1 (33%)	3 (50%)	0	1 (25%)
	Blood triglycerides increased	1 (33%)	0	1 (33%)	2 (50%)
	Neutrophil count decreased	1 (33%)	2 (33%)	0	1 (25%)
	Blood uric acid increased	1 (33%)	1 (17%)	1 (33%)	0
	Alanine aminotransferase increased	1 (33%)	0	0	1 (25%)
	Blood bilirubin increased	0	1 (17%)	1 (33%)	0
	Low density lipoprotein increased	0	0	0	1 (25%)
	Lymphocyte percentage decreased	0	1 (17%)	0	0
	Monocyte count decreased	0	0	0	1 (25%)
	Neutrophil count increased	0	1 (17%)	0	0
	Platelet count increased	1 (33%)	0	0	0
	White blood cells urine positive	0	0	0	1 (25%)
	Infections and infestations	1 (33%)	0	0	2 (50%)
	Nasopharyngitis	1 (33%)	0	0	1 (25%)
	Periodontitis	1 (33%)	0	0	0
	Tooth infection	0	0	0	1 (25%)
	Gastrointestinal disorders	0	1 (17%)	0	0
	Diarrhoea	0	1 (17%)	0	0
	Musculoskeletal and connective tissue disorders	0	1 (17%)	0	0
Pain in extremity	0	1 (17%)	0	0	
BR11-198	Investigations	3 (100%)	4 (67%)	0	3 (75%)
	Blood triglycerides increased	0	4 (67%)	0	2 (50%)

Antibody	System Organ Class Preferred Term	750 mg (n=3)	1500 mg (n=6)	3000 mg (n=3)	Placebo (n=4)
	Blood bilirubin increased	1 (33%)	2 (33%)	0	0
	White blood cell count decreased	1 (33%)	1 (17%)	0	1 (25%)
	Alanine aminotransferase increased	1 (33%)	1 (17%)	0	0
	Blood creatine phosphokinase increased	0	1 (17%)	0	0
	Blood uric acid increased	0	0	0	1 (25%)
	Aspartate aminotransferase increased	0	1 (17%)	0	0
	Injury, poisoning and procedural complications	0	0	0	1 (25%)
	Foot fracture	0	0	0	1 (25%)
	Ear and labyrinth disorders	0	0	0	1 (25%)
	Cerumen impaction	0	0	0	1 (25%)
	Gastrointestinal disorders	1 (33%)	1 (17%)	0	0
	Abdominal pain upper	1 (33%)	0	0	0
	Constipation	0	1 (17%)	0	0
	Infections and infestations	0	0	0	1 (25%)
	Otitis externa	0	0	0	1 (25%)
	Musculoskeletal and connective tissue disorders	0	0	0	1 (25%)
	Arthralgia	0	0	0	1 (25%)

Participants who experienced the same AE on more than one occasion (based on the specific category) are counted once in each relevant category. Percentages are based on the number of participants in the treatment group.

Supplementary Table 3. Treatment-related Adverse Events by Preferred Term.

Antibody	Preferred Term	750 mg (n=3)	1500 mg (n=6)	3000 mg (n=3)	Placebo (n=4)
BR11-196	White blood cell count decreased	0	1 (17%)	0	0
	Neutrophil count decreased	0	1 (17%)	0	0
	Alanine aminotransferase increased	1 (33%)	0	0	0
	Blood bilirubin increased	0	1 (17%)	0	0
BR11-198	Alanine aminotransferase increased	1 (33%)	0	0	0
	Blood bilirubin increased	1 (33%)	1 (17%)	0	0

Participants who experienced the same AE on more than one occasion (based on the specific category) are counted once in each relevant category. Percentages are based on the number of participants in the treatment group.

Supplementary Materials

Inclusion and Exclusion Criteria for BR11-196-001 and BR11-198-001 Studies

Inclusion Criteria

Subjects are eligible to be included in the study only if all of the following criteria apply:

Age

1. Subject must be 18 to 49 years of age inclusive, at the time of signing the informed consent.

Type of Subjects

2. Subjects who are healthy as determined by medical evaluation including medical history, full physical examination, laboratory tests, and cardiac monitoring using 12-lead ECG, and have venous access sufficient to allow for blood sampling as per the protocol.

Weight

3. Body weight ≤ 100 kg and body mass index (BMI) within the range of 19.0-24.0kg/m² (inclusive). The weight of male subjects shall be no less than 50kg, and that of female subjects shall be no less than 45kg.

Sex

4. Male and female

Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Male subjects:

- i. Male subjects with female partners of childbearing potential must agree to meet one of the following contraception requirements from the time of study agent administration through the end of the study:
 - total abstinence, or
 - vasectomy with documentation of azoospermia, or
 - barrier form of contraception with spermicide, or
 - female partner use of an intrauterine device or hormonal contraceptives including oral, implantable, injectable or transdermal contraceptives within 30 days prior to male subject signing the informed consent form (ICF).
- ii. Male subjects must also agree not to donate sperm through the end of the study.

Female subjects:

- i. A female subject is eligible to participate if she is:
 - of non-childbearing potential, defined as premenarchal, or premenopausal with a documented hysterectomy, or bilateral tubal ligation or oophorectomy.
 - of childbearing potential, not breastfeeding and agrees to use one of the following acceptable methods of contraception through the end of the study:
 - total abstinence, or

- barrier form of contraception such as condom or occlusive cap with spermicide, or
 - an intrauterine device, or hormonal contraceptives including oral, implantable, injectable or transdermal contraceptives initiated at least within 30 days prior to signing the ICF.
- ii. Woman of Childbearing Potential* (WOCBP) must have a negative serum pregnancy test at screening and a negative serum pregnancy test on Day 1 prior to study treatment (within 24 hours) administration.

Error! Reference source not found.

Informed Consent

5. Capable of giving signed informed consent as described in **Error! Reference source not found.** the protocol which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Other Inclusions

6. Agrees to not donate blood during the duration of the study.
7. Agrees not to increase physical activity for 4 weeks after study agent administration.

Exclusion Criteria

Subjects are excluded from the study if any of the following criteria apply:

Medical Conditions

1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neoplastic (with the exception of basal or squamous cell cancer), neurological, or psychiatric disorder (as determined by the Investigator) capable of significantly altering the absorption of drugs; of constituting a risk when taking the study intervention; or of interfering with the interpretation of the data.
2. SARS-COV-2 exposure history or clinical history of COVID-19, including positive COVID-19 RNA test one week before screening or at screening.
3. History of previous diagnosis of SARS.
4. Any history of a severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis prior to enrollment that has a reasonable risk of recurrence during the study.
5. A history of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator.
6. Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with blood draws.
7. Any major surgical procedure or hospitalization within 3 months prior to Day 1 or during the study, unless deemed not clinically significant by the Investigator.
8. History or presence of an abnormal ECG which, in the Investigator's opinion, is clinically significant.

9. History of alcohol or other substance abuse within 1 year prior to screening according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition criteria, or recent use of drugs of abuse or a positive urine screen for drugs of abuse at screening.
10. History of depression or suicidal thoughts and/or behaviors within 1 year prior to screening.
11. History of clinically significant chronic liver disease from any cause, presence of hepatitis B surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, or syphilis antibody.

Prior/Concomitant Therapy

12. Use prescription drugs within 14 days before Day 1, or expected in the course of the study.
13. Use of antiplatelet, anticoagulant, or antiepileptic medications within 30 days prior to Day 1, or expected in the course of the study.
14. Received immunoglobulin or blood products in the 6 months prior to Day 1, or expected in the course of the study.
15. Received any vaccine within 14 days prior to Day 1 through 180 days after dosing in the study.
16. Use of over the counter (OTC) medication or herbal remedy, e.g., Traditional Chinese Medicine, within 14 days before Day 1, or expected in the course of the study.

Prior/Concurrent Clinical Study Experience

17. Received an investigational agent or provided clinical samples for clinical studies within 90 days or 5 half-lives of the investigational agent whichever is longer, before screening or are active in the follow-up phase of another clinical study involving interventional treatment. Subjects must also agree not to take part in any other study at any time during their participation in this study, inclusive of the follow-up period.
18. Previous receipt of a licensed or investigational monoclonal antibody within 5 half-lives or 6 months prior to screening, whichever is longer.

Diagnostic assessments

19. Systolic blood pressure >140 mmHg or a diastolic blood pressure of >90 mmHg after approximately 10 minutes resting at screening.
20. Calculated glomerular filtration rate of <60 mL/min/1.73m² by estimated glomerular filtration rate (eGFR) using standardized local clinical methodology.

Other Exclusions

21. Has an average weekly alcohol intake that exceeds 21 units of alcohol per week (males) or 14 units per week (females) within 30 days prior to screening. One unit: 1 glass of wine 5 oz or 150 mL; 12 oz or 360 mL of beer; 1.5 oz or 45 mL of distilled spirits.
22. Are unwilling to stop alcohol consumption within 72 hr prior to Day 1 (as confirmed by alcohol breath screen) or expected for the 24 hr post-dose period.

23. Need special dietary restrictions, unless the restrictions are approved by the Investigator and/or Bii Biosciences.
24. Any conditions which, in the opinion of the Investigator, would make the subject unsuitable for enrollment or could interfere with the subject's participation in or completion of the study.
25. Donated blood within 90 days before screening.

Definition of Woman of Childbearing Potential (WOCBP)

A woman is considered fertile following menarche and until becoming post-menopausal unless permanently sterile (see below).

If fertility is unclear (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be confirmed before first dose of study intervention, additional evaluation should be considered.

Women in the following categories are not considered WOCBP

1. Premenarchal
2. Premenopausal female with 1 of the following:
 - Documented hysterectomy
 - Documented bilateral salpingectomy
 - Documented bilateral oophorectomy

For individuals with permanent infertility due to an alternate medical cause other than the above, (e.g., mullerian agenesis, androgen insensitivity), Investigator discretion should be applied to determining study entry.

Note: Documentation can come from the site personnel's: review of the subject's medical records, medical examination, or medical history interview.

3. Postmenopausal female
 - A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
 - A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy (HRT).
 - Females on HRT and whose menopausal status is in doubt will be required to use one of the non-estrogen hormonal highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.